This page tracks new and upcoming treatment options for Charcot-Marie-Tooth disease (CMT). What’s in development? What’s promising? What’s available soon? Current topics include PXT3003, SIPA1L2, HDAC3 inhibitors, HDAC6, VM202 (Engensis), IFB-088 (Sephin1), aminoacyl-tRNA synthetases (aaRS), SW-100, SARM1 inhibitors, NTF3, gene therapy, PMP22, KU-596, and more. Jump to section: News, Research, Clinical Trials, Projects, Patents, Discussion
Last updated: 15 hours ago
Subscribe
News
Research
A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice May 17, 2022
Molecular characterization of Turkish patients with demyelinating Charcot-Marie-Tooth disease May 13, 2022
Do different foot types affect the 6-min walk test capacity of younths with Charcot-Marie-Tooth neuropathy ? May 12, 2022
Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1) May 5, 2022
Structural insights into Charcot-Marie-Tooth disease-linked mutations in human GDAP1 May 4, 2022
Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice May 2, 2022- Novel de novo POLR3B mutations responsible for demyelinating Charcot-Marie-Tooth disease in Japan Apr 28, 2022
- Generation of a human induced pluripotent stem cell (iPSC) line (JUCTCi019-A) from a patient with Charcot-Marie-Tooth disease type 2A2 (CMT2A2) due to a heterozygous missense substitution c.2119C > T (p.Arg707Trp) in MFN2 gene Apr 12, 2022
Dosage effects of PMP22 on nonmyelinating Schwann cells in hereditary neuropathy with liability to pressure palsies Apr 8, 2022- The Antiepileptic Valproic Acid Ameliorates Charcot-Marie-Tooth 2W (CMT2W) Disease-Associated HARS1 Mutation-Induced Inhibition of Neuronal Cell Morphological Differentiation Through c-Jun N-terminal Kinase Apr 5, 2022
- Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor Mar 30, 2022
- Curcumin and Ethanol Effects in Trembler-J Schwann Cell Culture Mar 29, 2022
- The Role of Impaired Mitochondrial Dynamics in MFN2-Mediated Pathology Mar 24, 2022
- HDAC3 Inhibition Stimulates Myelination in a CMT1A Mouse Model Mar 23, 2022
- Mitochondrial Phenotypes in Genetically Diverse Neurodegenerative Diseases and Their Response to Mitofusin Activation Mar 21, 2022
- Clinical genetics of Charcot–Marie–Tooth disease Mar 18, 2022
- Unexpected Intermediate Nerve Conduction Velocity Findings in Charcot-Marie-Tooth Syndromes Classified as Demyelinated or Axonal in a Pediatric Population Mar 16, 2022
- DNAJB2-related Charcot-Marie-Tooth disease type 2: Pathomechanism insights and phenotypic spectrum widening Mar 14, 2022
- Multiubiquitination of TRPV4 reduces channel activity independent of surface localization Mar 14, 2022
- Mitochondria-lysosome contact site dynamics and misregulation in neurodegenerative diseases Mar 3, 2022
- Acute to Subacute Atraumatic Entrapment Neuropathies in Patients With CMT1A: A Report of a Distinct Phenotypic Variant of CMT1A Feb 25, 2022
- Early targeting of endoneurial macrophages alleviates the neuropathy and affects abnormal Schwann cell differentiation in a mouse model of Charcot-Marie-Tooth 1A Feb 21, 2022
- Structural insights into Charcot-Marie-Tooth disease-linked mutations in human GDAP1 [preprint] Feb 18, 2022
- Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons Feb 14, 2022
- A splice altering variant in NDRG1 gene causes Charcot-Marie-Tooth disease, type 4D Feb 11, 2022
- NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice Feb 10, 2022
- Neuropathic pain in Charcot-Marie-Tooth Disease Feb 7, 2022
- Autophagy and Lysosomal Functionality in CMT2B Fibroblasts Carrying the RAB7K126R Mutation Jan 31, 2022
- Cytokines secreted by mesenchymal stem cells reduce demyelination in an animal model of Charcot-Marie-Tooth disease Jan 28, 2022
SARM1 Knockout Does Not Rescue Neuromuscular Phenotypes in a Charcot-Marie-Tooth Disease Type 1A Mouse Model Jan 28, 2022- Imbalance of Neuregulin1-ErbB2/3 signaling underlies altered myelin homeostasis in models of Charcot-Marie-Tooth disease type 4H [preprint] Jan 22, 2022
- Therapeutic Strategies Targeting Mitochondrial Calcium Signaling: A New Hope for Neurological Diseases? Jan 15, 2022
- The protective role of mesencephalic astrocyte-derived neurotrophic factor in endoplasmic reticulum stress in RT4-D6P2T schwannoma sells with the S63del MPZ mutation Jan 4, 2022
- An Integrated Approach to Studying Rare Neuromuscular Diseases Using Animal and Human Cell-Based Models Jan 3, 2022
- HDAC6 Inhibition Corrects Electrophysiological and Axonal Transport Deficits in a Human Stem Cell-Based Model of Charcot-Marie-Tooth Disease (Type 2D) Dec 26, 2021
- A mutation associated with Charcot-Marie-Tooth disease enhances the formation of stable dynamin 2 complexes in cells [preprint] Dec 13, 2021
- A longitudinal and cross-sectional study of plasma neurofilament light chain concentration in Charcot-Marie-Tooth disease Dec 1, 2021
- Demyelination induces transcriptional reprograming in proprioceptive and Aβ rapidly adapting low-threshold-mechanoreceptor neurons [preprint] Nov 23, 2021
- Inversely proportional myelin growth due to altered Pmp22 gene dosage identifies PI3K/Akt/mTOR signaling as a novel therapeutic target in HNPP [preprint] Nov 8, 2021
- Mechanisms and Treatments in Demyelinating CMT Nov 8, 2021
- Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives Oct 29, 2021
- Medicinal chemistry updates of novel HDACs inhibitors (2020 to present) Oct 22, 2021
- Treatment with IFB-088 improves neuropathy in CMT1A and CMT1B mice [preprint] Oct 18, 2021
- A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A Oct 16, 2021
- Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities Oct 4, 2021
Clinical Trials
- Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A Apr 19, 2022
- Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PREMIER) Mar 23, 2022
- Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A [Suspended] Mar 16, 2022
- A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A Mar 2, 2022
Projects
- Control of calcium flux and mitochondrial fission by the Charcot Marie Tooth disease protein Mfn2 Dec 31, 2025
- Laminin receptors and signals in Schwann cells Dec 31, 2025
- Exploring the Functions of tRNA Synthetases in the Nucleus and their Relationship to CMT Mar 31, 2025
- The Role of ESCRTs in Regulating Nervous System Function Nov 30, 2024
- Genomic Studies in Charcot-Marie-Tooth Disease Jul 31, 2024
- Accelerate Clinical Trials in CMT (ACTCMT) Study Feb 29, 2024
- Creation of a Schwann Cell Gene Regulatory Network Feb 28, 2024
- Restoring Neurofilaments to Axons in a Mouse Model of CMT2E Feb 28, 2023
- Targeting the PMP22 Protein to Develop Leads Against Charcot-Marie-Tooth Disease Dec 31, 2022
- Actin-mediated regulation of organelle dynamics in Charcot-Marie-Tooth disease Dec 31, 2022
- Investigating SIPA1L2 as a Modifier Gene and Therapeutic Target for Charcot-Marie-Tooth Type 1A Jul 31, 2022
Patents
- Treatment of charcot-marie-tooth axonal type 2d using nt-3 gene therapy Oct 21, 2021
- Pharmaceutical composition for preventing or treating Charcot-Marie-Tooth disease comprising insulin secreted from mesenchymal stem cells or mesenchymal stem cells Sep 29, 2021
- tRNA OVEREXPRESSION AS A THERAPEUTIC APPROACH FOR CHARCOT-MARIE-TOOTH NEUROPATHY ASSOCIATED WITH MUTATIONS IN tRNA SYNTHETASES Aug 12, 2021
